FDA grants orphan drug designation to CAR-T for mesothelioma

The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell therapy, for treatment of mesothelin-expressing mesothelioma.
SynKIR-110 (Verismo Therapeutics) is a gene-edited CAR T-cell therapy with next-generation dual-chain signaling.
The agent is based on Versimo’s proprietary KIR-CAR platform, which uses a modified natural killer (NK) cell-like receptor to improve T-cell persistence and efficacy against solid tumors.
"Mesothelioma is a rare and deadly disease for which few other treatment options currently exist,” Bryan Kim, DMD, CEO

The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell therapy, for treatment of mesothelin-expressing mesothelioma.
SynKIR-110 (Verismo Therapeutics) is a gene-edited CAR T-cell therapy with next-generation dual-chain signaling.
The agent is based on Versimo’s proprietary KIR-CAR platform, which uses a modified natural killer (NK) cell-like receptor to improve T-cell persistence and efficacy against solid tumors.
«Mesothelioma is a rare and deadly disease for which few other treatment options currently exist,” Bryan Kim, DMD, CEO